Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New Osteoporosis Drug Reduces Fracture Risk

By R&D Editors | April 5, 2016

Over the 18-month trial period, abaloparatide decreased new vertebral fractures by 86 percent, compared to teriparatide’s 80 percent; and reduced non-vertebral fractures by 43 percent, whereas teriparatide performed on par with the placebo. Often referred to as a “silent disease,” osteoporosis affects approximately 9 million Americans. A further 43 million Americans suffer from low-bone density. Often, people with the disease may not know they have it until they suffer a bone break or fracture.

A disease so ubiquitous comes with a hefty price tag. According to the National Osteoporosis Foundation, bone breaks related to the disease cost around $19 billion annually. By 2025, that amount could increase to $25.3 billion. 

The disease poses a substantial threat to postmenopausal women, as the lack of estrogen, a bone-protecting hormone, has a direct relationship with osteoporosis. A woman’s risk of hip fracture from osteoporosis, according to the National Osteoporosis Foundation, is on par with the combined risk of breast, uterine, and ovarian cancer.

“The disability after fracture can be incredible and not just hip (fracture),” said Dr. Lorraine Fitzpatrick, the chief medical officer of biopharmaceutical company Radius Health Inc., to R&D Magazine. “I’ve had ladies who use a walker and then they fall and break both wrists.” 

“Can you imagine how disabling that is?”

Recently, Fitzpatrick and Radius Health presented the results of Phase 3 ACTIVE trials for their investigational drug abaloparatide-SC, an injectable synthetic peptide analog of human parathyroid hormone-related protein, which is critical to the formation of the skeleton. The presentation was given at Endocrine Society 2016 Annual Meeting in Boston. 

Abaloparatide showed consistent protection against bone fractures, and increased bone mineral density in a broad group of postmenopausal women with osteoporosis, Fitzpatrick said.

The trial consisted of more than 2,400 postmenopausal women between the ages of 49- and 86-years-old. The patients were either treated with a placebo, abaloparatide, or teriparatide. The latter is currently approved to combat the silent disease.

Over the 18-month trial period, abaloparatide decreased new vertebral fractures by 86 percent, compared to teriparatide’s 80 percent; and reduced non-vertebral fractures by 43 percent, whereas teriparatide performed on par with the placebo.

Additionally, patients who took abaloparatide in the study showed greater increases in bone mineral density at the total hip and femoral neck sites.

Radius Health submitted a New Drug Application to the U.S. Food and Drug Administration on March 30, and the drug is currently undergoing regulatory review by the European Medicines Agency.     

Like any drug, abaloparatide does have side effects, including hypercalcemia, dizziness, and palpitations. Both palpitations and hypercalcemia are known side effects of teriparatide. Although, “our amount of hypercalcemia was half of that of teriparatide,” Fitzpatrick added.

“If we can catch this earlier in the course of the disease and treat (patients), we’ll make their lives much more rewarding in their older years,” Fitzpatrick concluded.

Radius Health is in early development of a patch version of the drug.

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community! Learn more.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE